Amir Hadi Maghzi, MD

Assistant Professor, Neurology

Amir Maghzi
617.789.3000
72 E. Concord Street

Biography

Dr. Maghzi has a longstanding interest in multiple sclerosis and has published on various aspects of the disease since he started in 2006. He is currently performing basic research in understanding the gut-brain axis in MS.

Publications

  • Published on 7/24/2024

    Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Domingo-Horne R, Toukam M, Nunn A, Maghzi AH, Kuhelj R, Lasky T. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2). Neurol Ther. 2024 Oct; 13(5):1385-1401. PMID: 39046635.

    Read at: PubMed
  • Published on 7/18/2023

    Abou-El-Hassan H, Rezende RM, Izzy S, Gabriely G, Yahya T, Tatematsu BK, Habashy KJ, Lopes JR, de Oliveira GLV, Maghzi AH, Yin Z, Cox LM, Krishnan R, Butovsky O, Weiner HL. V?1 and V?4 gamma-delta T cells play opposing roles in the immunopathology of traumatic brain injury in males. Nat Commun. 2023 Jul 18; 14(1):4286. PMID: 37463881.

    Read at: PubMed
  • Published on 9/1/2022

    Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N'Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH. Effect of Dimethyl Fumarate vs Interferon ß-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. JAMA Netw Open. 2022 Sep 01; 5(9):e2230439. PMID: 36169959.

    Read at: PubMed
  • Published on 5/20/2021

    Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul; 8(4). PMID: 34016734.

    Read at: PubMed
  • Published on 4/30/2021

    Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, Anderson MC, De Jager PL, Polgar-Turcsanyi M, Healy BC, Glanz BI, Bakshi R, Chitnis T, Weiner HL. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 Jun; 89(6):1195-1211. PMID: 33876477.

    Read at: PubMed
  • Published on 10/13/2020

    Maghzi AH, Weiner HL. A One-Two Punch in the Gut May Trigger Multiple Sclerosis. Immunity. 2020 Oct 13; 53(4):707-709. PMID: 33053328.

    Read at: PubMed
  • Published on 6/11/2020

    Maghzi AH, Sicotte NL, Waubant E. Do you believe in Gad? Mult Scler Relat Disord. 2020 Sep; 44:102299. PMID: 32593143.

    Read at: PubMed
  • Published on 6/3/2020

    Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Oct; 267(10):2790-2796. PMID: 32494856.

    Read at: PubMed
  • Published on 5/23/2020

    Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Disord. 2020 Aug; 43:102222. PMID: 32464586.

    Read at: PubMed
  • Published on 5/5/2020

    Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm. 2020 Jul; 7(4). PMID: 32371550.

    Read at: PubMed

View 57 more publications: View full profile at BUMC

View all profiles